Table 1.

Subject Demographics and Baseline Characteristics of the Safety Population (N = 305)

Characteristic	Methylphenidate Transdermal System
Age, mean (± SD), y	9.1 (1.9)
Age, n (%), y
6–9	168 (55.1)
10–12	137 (44.9)
Gender, male, n (%)	215 (70.5)
Ethnicity, n (%)
Hispanic/Latino	73 (23.9)
Not Hispanic/Latino	232 (76.1)
Race/ethnicity, n (%)
White	237 (77.7)
Black/African American	35 (11.5)
Native Hawaiian/Pacific Islander	3 (1.0)
Asian	2 (0.7)
Other	28 (9.2)
Weight, mean (± SD), lb	73.1 (21.2)
Height, mean (± SD), in	53.6 (5.1)
Body mass index, mean (± SD)	17.5 (2.4)
ADHD-RS-IV score, mean (± SD)	42.2 (8.0)
CGI-S score, mean (± SD)	4.9 (0.8)

Abbreviations: ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder Rating Scale-IV, CGI-S = Clinical Global Impressions-Severity of Illness scale.